Jumping translocations of 1q in donor cell‑derived myelodysplastic syndrome after cord blood transplantation: Case report and review of the literature

  • Authors:
    • Toshinori Kondo
    • Taizo Tasaka
    • Risa Shimizu
    • Kiyohito Hayashi
    • Seiko Yamada
    • Hirofumi Fukuda
    • Tadashi Hirose
    • Asako Takeuchi
    • Fuminori Sano
    • Hirotoshi Tokunaga
    • Yoshiko Matsuhashi
    • Hideho Wada
  • View Affiliations

  • Published online on: February 6, 2020     https://doi.org/10.3892/mco.2020.1995
  • Pages: 365-373
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Donor cell‑derived leukemia and myelodysplastic syndrome (DCL) is a rare complication in patients after allogenic stem cell transplantation (SCT). Since 1971, numerous cases of DCL have been reported, but the detailed mechanisms of DCL are still unclear. A patient with jumping translocations (JTs) of 1q in umbilical cord blood donor cell‑derived myelodysplastic syndrome (MDS), which likely occurred due to genetic alterations of TET2 and ASXL1 after cord blood transplantation (CBT), was examined in this study. Previously reported DCL cases after CBT that focused on the cytogenetic and molecular characteristics of these patients and patient outcome were reviewed. A total of 30 cases of DCL after CBT were identified between 2005 and 2018. The median time from CBT to the development of DCL was 16 months. The number of patients with DCL who were diagnosed with acute myeloid leukemia (AML) and MDS was 19 and 8, respectively. JTs were frequently observed in 5 of 27 DCL patients who had cytogenetic abnormalities, including our patient. Molecular abnormalities were described in 7 of the cases, and the most frequent abnormality was an NPM1 mutation. Other gene mutations that were usually found in de novo MDS or AML were observed in JT-DCL after CBT. From these results, chromosomal abnormalities such as JTs that occur subsequent to genetic alterations were seemed an important mechanisms underlying DCL onset in patients after CBT. Further molecular analyses regarding the genetic alterations of JTs are required to understand the pathogenesis of umbilical cord blood‑derived JT‑DCL.

Related Articles

Journal Cover

April 2020
Volume 12 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Kondo, T., Tasaka, T., Shimizu, R., Hayashi, K., Yamada, S., Fukuda, H. ... Wada, H. (2020). Jumping translocations of 1q in donor cell‑derived myelodysplastic syndrome after cord blood transplantation: Case report and review of the literature. Molecular and Clinical Oncology, 12, 365-373. https://doi.org/10.3892/mco.2020.1995
MLA
Kondo, T., Tasaka, T., Shimizu, R., Hayashi, K., Yamada, S., Fukuda, H., Hirose, T., Takeuchi, A., Sano, F., Tokunaga, H., Matsuhashi, Y., Wada, H."Jumping translocations of 1q in donor cell‑derived myelodysplastic syndrome after cord blood transplantation: Case report and review of the literature". Molecular and Clinical Oncology 12.4 (2020): 365-373.
Chicago
Kondo, T., Tasaka, T., Shimizu, R., Hayashi, K., Yamada, S., Fukuda, H., Hirose, T., Takeuchi, A., Sano, F., Tokunaga, H., Matsuhashi, Y., Wada, H."Jumping translocations of 1q in donor cell‑derived myelodysplastic syndrome after cord blood transplantation: Case report and review of the literature". Molecular and Clinical Oncology 12, no. 4 (2020): 365-373. https://doi.org/10.3892/mco.2020.1995